Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
Johnson & Johnson (JNJ) Stock Draws Fresh Price Target Split On Pipeline Promise And Policy Risk
20.06.2026 02:06
Johnson & Johnson’s model fair value sits at US$252.87 per share, with analysts keeping price targets anchored to that unchanged estimate. Recent research links those steady targets to a mix of optimism around Icotyde, Inlexzo and the broader drug pipeline, balanced against policy questions and partnership headwinds that could influence how investors think about execution risk. As you read on, you will see how these moving pieces shape the evolving Johnson & Johnson story and what to watch...
J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?
19.06.2026 12:07
J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.
Insomnia Market Witnesses Robust Growth During the Forecast Period (2026-2036) with Emerging Orexin Receptor Antagonists and Melatonin Receptor Agonist | DelveInsight
18.06.2026 16:31
Recently published Insomnia Market Insights report includes a comprehensive understanding of current treatment practices, insomnia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
50 Years of Dividend Hikes: These Stocks Did It
18.06.2026 05:15
The Dividend Kings include more than 50 stocks with steadily rising payouts. They’re hard to beat for dividend safety.
Johnson & Johnson to Invest Over $1 Billion in Florida Contact Lens Manufacturing Facility
18.06.2026 01:16
With a net profit margin of 21.83%, Johnson & Johnson (NYSE:JNJ) is included among the 12 Most Profitable American Stocks to Buy in 2026. Johnson & Johnson (NYSE:JNJ) and its subsidiaries develop, manufacture, and sell a broad range of healthcare products, giving the company a presence across multiple areas of the healthcare industry. The company’s dividend […]
AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication
15.06.2026 12:59
AZN wins FDA approval to expand Truqap's use in PTEN-deficient prostate cancer, backed by phase III data showing improved outcomes and broader use.
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
15.06.2026 10:00
NEW BRUNSWICK, N.J., June 15, 2026--Johnson & Johnson (NYSE: JNJ) (the "Company"), healthcare’s leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billion in Jacksonville, Florida to strengthen its Vision operations by scaling U.S.-based manufacturing, packaging and distribution capabilities.
Johnson & Johnson Plans $1B+ Florida Investment To Strengthen Its Vision Operations By Scaling Up Its Manufacturing, Packaging And Distribution Capabilities
15.06.2026 06:02
Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company's U.S. Vision operations, enhance supply chain resilience, and meet the
Reported Saturday, Johnson & Johnson's TALVEY Plus DARZALEX FASPRO Delivers Up To 81% PFS And 89% OS At 24 Months In First Phase 3 Study To Show Superior PFS For GPRC5D Bispecific Combination In Multiple Myeloma
15.06.2026 03:19
TALVEY plus DARZALEX FASPRO with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the third positive study in recent months
BlackBerry QNX Extends Beyond Autos As Valuation Runs Ahead Of Targets
14.06.2026 07:13
BlackBerry's QNX software has secured new deployments in industrial automation, robotics, and medical AI. The QNX platform is being adopted in a new AI powered heart pump developed by Johnson & Johnson. These wins extend QNX beyond its traditional automotive base into additional embedded and safety critical use cases. For investors watching TSX:BB, this QNX expansion comes with the stock at CA$12.86 and strong recent momentum. The share price is up 51.3% over the past 30 days, 146.4% year...
Johnson & Johnson (JNJ) to Acquire Firefly Bio for $1B
13.06.2026 10:39
Johnson & Johnson (NYSE:JNJ) is one of the 7 Best Longevity Stocks to Buy Now. On June 8, 2026, Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Firefly Bio, Inc. for $1B in cash. Firefly Bio is advancing its proprietary Firelink degrader antibody conjugate platform, which is focused on KRAS-driven tumors. Johnson […]
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
13.06.2026 10:33
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced results from the investigational Phase 3 MonumenTAL-3 study showing that TALVEY® (talquetamab-tgvs), a GPRC5D bispecific antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72% and clinically meaningful reduction of up to 53% in the risk of death compared
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal
13.06.2026 08:46
Protagonist Therapeutics (PTGX) outlook: FDA catalysts, milestone payments, high-margin royalties & strong cash runway through 2028.
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
11.06.2026 06:03
Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistically significant durable hemoglobin (Hgb) responseb with rapid onset of effect in patients with warm autoimmune hemolytic anemia (wAIHA)e in the 30 mg/kg treatment group,a compared with those who received placebo. The randomized, placebo-controlled trial demonstrated approximately three times as many patients achieved durabl
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
11.06.2026 06:03
Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistically significant durable hemoglobin (Hgb) responseb with rapid onset of effect in patients with warm autoimmune hemolytic anemia (wAIHA)e in the 30 mg/kg treatment group,a compared with those who received placebo. The randomized, placebo-controlled trial demonstrated approximately three times as many patients achieved durabl
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
10.06.2026 15:22
LOS ANGELES, June 10, 2026--A Los Angeles jury has awarded $32 million to the family of a California woman who died from pleural mesothelioma after years of exposure to an asbestos-contaminated talc product, finding Johnson & Johnson (NYSE: JNJ) and its subsidiaries liable for her illness.
FesariusTherapeutics Closes Oversubscribed $20M Series A, Led by Jefferson Life Sciences, and Backed by NY Ventures, and the American Society of Plastic Surgeons
10.06.2026 12:00
FesariusTherapeutics, a commercial-stage medical technology company reimagining dermal repair, today announced the close of an oversubscribed $20 million Series A financing round. The round was anchored by Jefferson Life Sciences (JLS) and joined by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.), Empire State Development's NY Ventures, and the American Society of Plastic Surgeons (ASPS), marking its inaugural institutional invest
Jim Cramer Applauds Johnson & Johnson’s “Great New Drug Profits, Triple-A Balance Sheet”
10.06.2026 11:36
Johnson & Johnson (NYSE:JNJ) was among the stocks Jim Cramer discussed on Mad Money, along with the recent sell-off in the market. Cramer was bullish on the stock during the episode, as he said: Now, you can make good money for a while if you go all in on what’s hot, but I never do […]
J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline
09.06.2026 10:59
The transaction is expected to close later this year, subject to regulatory approvals and other customary closing conditions.
J&J secures extended NICE approval for Darzalex following earlier refusal
09.06.2026 09:47
NICE has preliminarily recommended D-VRd for NHS use as a first-line treatment for transplant-ineligible multiple myeloma.